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A joint workshop held by Cancer Research UK and the Medical Research Council aimed to stimulate interest in further research into
the area of cancer cachexia. The workshop was divided into four sessions: an overview of cancer cachexia, potential mechanisms
involved and methodologies that might be used to understand cachexia, and also the experience of cachexia from other disease
areas. The workshop identified a need to develop a multimodal therapeutic approach to cancer cachexia and a need to undertake
more multidisciplinary research.
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BACKGROUND TO THE WORKSHOP
In 2002, Cancer Research UK (CR UK) undertook a strategic
review of issues facing cancer research. The review highlighted a
lack of research activity and understanding of the physiological
mechanisms of whole-body responses to the presence of a tumour
including cancer cachexia. Following discussions with the Medical
Research Council (MRC), both funders agreed to hold a joint
workshop on cancer cachexia as an initial step in raising the profile
and stimulating high-quality research in this area. The aims of the
Workshop would be to introduce issues in cancer cachexia
research to a wider UK clinical oncology research audience, and
to highlight research methodologies that might be used to
investigate cachexia in cancer patients and to draw on the
experiences and progress of cachexia research in other disease
areas.
PRESENTATIONS
The Workshop presentations were divided into four sessions: an
overview, a review of the potential mechanisms involved in cancer
cachexia, methodologies that might be used to assess and
understand cachexia, and the experience and knowledge of
researchers from other disease areas.
OVERVIEW
Professor Robert Souhami of CR UK introduced the workshop
by saying that an understanding of the underlying mechanisms was
a prerequisite to the development of therapeutic interventions in
cachexia. For this reason, the workshop would explore possibilities
for UK collaborative research embracing oncologists, scientists with
expertise in intermediary metabolism and acute-phase response
(APR), and also scientists with relevant specific technological
expertise and those in the field of biochemistry and physiology.
Cancer cachexia: mechanisms and clinical implications
Professor Kent Lundholm (Go ¨teborg, Sweden) described how
resting energy expenditure (REE) was significantly increased
compared to controls (patients with chronic inflammation who
experienced some weight loss). Fundamental changes in metabo-
lism, especially fat oxidation, appear to be related to the anorexia
and stress response that cachectic patients experience. The likely
explanation for weight loss was depressed protein synthesis, rather
than increased protein breakdown. He suggested that the weight
loss experienced by cancer cachexia patients was not caused
primarily by a decrease in food intake (anorexia) in all patients,
and suggested that patients may need to decrease their physical
activity to preserve body mass (Boaseus et al, 2001).
In discussion, the question was raised as to how a reduction in
physical activity might help attenuate weight loss in cancer
cachexia patients, since a reduction in physical activity would
result in reduced lean body mass (LBM). While Professor
Lundholm agreed that this was true, he pointed out that if cancer
patients do not compensate by increased eating then physical
activity would accelerate weight loss.
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Molecular mechanisms of cancer cachexia
Professor Josep Argile ´s (University of Barcelona, Spain) described the
anorexia-cachexia syndrome as being characterised by marked
weight loss, anorexia, asthenia and anaemia, leading to a mal-
nourished state (Argiles et al, 2003). This was caused by the induction
of anorexia and an accelerated catabolic state which in turn promotes
severe metabolic disturbances in the host, including hypermetabo-
lism, associated with increased energetic inefficiency and increased
thermogenesis. A tumour has a high demand for glucose which is
supplied via breakdown of adipose and lean tissue. The breakdown of
adipose tissue may also release cytokines, growth factors and acute-
phase proteins which may also influence metabolism.
He concluded that a better understanding of the role of
cytokines, which interfered with the molecular mechanisms
accounting for protein wasting in skeletal muscle, was essential
for the design of future effective therapeutic strategies.
Biochemistry mechanism of tissue catabolism
Professor Mike Tisdale (Aston University) suggested that in
cachectic patients lipid-mobilising factor (LMF) may stimulate
uncoupling proteins which may utilise excess lipid that has been
mobilised during fat catabolism.
Proteolysis-inducing factor (PIF) causes catabolism of skeletal
muscle. Proteolysis-inducing factor initiates intracellular protein
degradation in skeletal muscle and inhibits protein synthesis
(Whitehouse and Tisdale, 2003). Both LMF and PIF could be
described as tumour catabolic factors and may play a role in
cancer cachexia.
Cancer cachexia and the APR
Professor Ken Fearon (Edinburgh University) confirmed that pro-
inflammatory cytokines such as IL1 and IL6 have long been
established as playing a major role in experimental models of the
cachexia syndrome. The APR represents a marker of proinflam-
matory cytokine activity in vivo and may also be a mechanism
contributing to weight loss in cancer. Recent evidence links the
presence of an APR with both the anorexia and hypermetabolism
in cachectic patients (Wigmore et al, 1997).
Professor Fearon suggested that systemic inflammation had
been shown to be an adverse risk factor for survival in advanced
cancer and was, therefore, a valid target as part of a multimodal
approach to the treatment of cancer. However, it was not clear
what initiated systemic inflammation in cancer.
Grehlin: a promising approach
Professor Bloom (ICSM, Hammersmith Hospital) stated that
ghrelin is a hormone secreted from the gastric cells that stimulates
food intake in healthy volunteers at physiological concen-
trations. He had investigated whether the effect of intravenous
ghrelin in cancer patients with appetite loss could be an effec-
tive treatment. Seven anorectic patients attended for a ghrelin
(5pmolkg
 1min
 1) infusion and a saline control in a randomised,
double-blinded study. Food intake from a buffet meal was mea-
sured after 90min of infusion. Patients rated the pleasantness of
the meal on a visual analogue scale. Energy intake from the buffet
meal was increased by 3177% (P¼0.02) on the ghrelin infusion
day, when every patient ate more, compared with saline infusion.
Patients also found the meal more pleasant on their ghrelin day
(23% increase of visual analogue score 78%; P¼0.02). This large
increase in energy intake suggests that regular ghrelin treatment
could be an effective treatment for patients with loss of appetite
(Neary et al, 2004).
General discussion
In the general discussion that followed this session, the APR
emerged as an area of potential interest. The discussion covered
the direct relationship of APR with the cachexia syndrome and to
what extent the production of APR is responsible for cachexia. In
addition, it was also pointed out that APR is now recognised as an
adverse prognostic indicator and that this is independent of stage
of disease.
The roles of nutrition support and chemotherapy were also
raised. Views on nutrition support in humans appeared mixed
with some evidence (from animal models) to suggest that nutrition
support decreased survival rates since it provides substrate for the
tumour, while others took the view that it had no adverse risks and
allowed patients to better tolerate aggressive anticancer therapies.
What remains to be proven is that reducing cancer cachexia per se
increases survival in cancer patients. Therefore, the importance of
retaining fat and LBM and reducing muscle wastage to improve
quality of life is paramount.
POTENTIAL METHODOLOGIES THAT MIGHT BE
USED TO ASSESS WEIGHT LOSS AND CHANGES IN
ENERGY METABOLISM
Measuring intermediary metabolism
Professor Ian Macdonald (University of Nottingham) outlined a
variety of techniques that are available to measure intermediary
metabolism in human subjects, ranging from whole body
assessments of energy expenditure, to studying local tissue or
organ uptake, oxidation and storage of specific metabolites.
However, most of the techniques to measure body composition
have been validated in normal individuals where body composi-
tion is not drastically altered (Jebb, 1995), rather than in cachectic
individuals.
Professor Macdonald said that cancer cachexia was associated
with substantial alterations in intermediary metabolism, both at
the local tissue and the whole-body level. An integrated approach
is required to determine the mechanisms underlying the develop-
ment of cachexia. This would combine whole-body and regional
measurements of metabolism and function, evaluating changes in
gene expression in tissues such as muscle and adipose tissue, and
establishing the role of cytokine and other molecules released from
tumours in mediating these alterations in metabolism.
Potential of stable isotopes: studies of human metabolism
Dr Andy Coward (MRC Human Nutrition Research) described the
principles behind the use of stable isotopes. Most elements exist in
more than one stable form and the less abundant ones can be used
as tracers. Thus, unlike the situation with radioactive isotopes,
which now have very limited use in human studies, there are very
few metabolic processes that are not amenable to investigation.
Limitations are imposed only by measurement technology, the
need for resilient models of the system under study and the
processes by which model parameters need to be translated into
clinically meaningful values. However, to make the best of the
current situation, the appropriate fit between clinical need and
technological capabilities always has to be found; thus the
modelling and translation processes are equally important
(Rennie, 1999). Where consensus for these exists, such as in
relation to the measurement of body composition by
2H2O dilution
or energy expenditure by
2H and
18O turnover in body water
(doubly labelled water (DLW) method), much progress has been
made. The DLW method measures the rate constants of the
disappearance of
18O and
2H from body water, converts these into
values for CO2 production and thence energy expenditure, but it
is pertinent to ask if these conversions, which represent the
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original turnover values are closest to the basic physiology.
Potential of magnetic resonance imaging (MRI) and
spectroscopy (MRS)
Professor Peter Morris (University of Nottingham) described MRI
as a highly developed technique that can examine the function of
both the cortex and the deeper grey matter in the brain. The basis
of the contrast, and hence clarity, in MRI is essentially the differing
levels of water content of each of the tissues, which tends to
increase in cancer. In addition, MRI can observe function through
detecting changes in blood oxidation. He suggested that changes in
LBM and adipose tissue in cancer patients may be measured at
specific body regions over time by selecting or suppressing the MR
signal from these tissues on the basis of their differing resonant
frequencies (Morris, 1999).
In addition to structural MRI, dynamic and functional assess-
ments are also possible, including flow, perfusion, diffusion,
cardiac performance, lung ventilation, gastric emptying and
functional neuro-imaging.
1H MRS enables the concentrations of
metabolites occurring at sufficiently high concentration (mM) to
be determined in regions of interest or low-resolution spectro-
scopic imaging studies.
Metabolic gas exchange measurements in patients with
chronic heart failure
Dr Andrew Clark (Hull University) presented a technique used to
measure metabolic gas exchange in heart failure cachexia. Cardiac
cachexia is common in heart failure patients and loss of lean tissue
is often observed early on in the disease. The rate of oxygen
consumption and CO2 production is determined experimentally
from the difference between inspired vs expired gas concentration,
and, at the same time, ventilation can also be measured. Exercise
capacity is reduced in chronic heart failure. This is characterised
by a reduction in peak oxygen consumption and an increase in the
ventilatory response to exercise, which is represented by an
increase in the slope of the relationship between ventilation and
carbon dioxide production. Dr Clark concluded by saying that
metabolic gas exchange measurements can be made using
straightforward, readily available equipment. The results give an
insight into energy metabolism at rest, but more particularly into
the physiology and pathophysiology of exercise performance
(Anker et al, 1997).
In the discussion, it emerged that, although there were some
striking similarities, no formal comparisons had been made
between cardiac cachexia and cancer cachexia.
LESSONS FROM OTHER AREAS
Gastro-intestinal inflammation
Professor Ian Sanderson (St Bartholomew’s and The Royal London
School of Medicine and Dentistry) said that children with Crohn’s
disease and children with cachexia both exhibited impaired
nutritional state, decreased fat and muscle mass. The inflammation
in Crohn’s disease also resulted in the expression of cytokines,
which could affect appetite, growth and energy expenditure.
Professor Sanderson described transgenic techniques that
allowed selective alterations of the expression of genes in the
intestinal epithelial cell. Thus, genetically engineered epithelial
expression of chemokines increased neutrophil recruitment, a
feature of Crohn’s disease. Furthermore, luminal molecules such as
short-chain fatty acids regulated chemokine expression (Sander-
son, 2004). This pathway from the lumen to the epithelium was one
example of how nutrients could alter intestinal inflammation.
Chronic heart failure
Dr Stefan Anker (National Heart and Lung Institute, London)
introduced this area by suggesting that the greater the body mass
index (BMI), the better the prognosis for survival in patients with
heart failure. Patients with cardiac cachexia had a poor prognosis,
as did those who were simply thin even in the absence of cachexia.
A 1% weight loss indicated a 12% increased risk of impaired
survival which was independent of BMI (Anker et al, 2003).
Dr Anker said that the pathophysiology of cardiac cachexia was
complex and involved neuroendocrine activation, hormone
resistance and lack of anabolism, and immune activation and
inflammation. Use of interventions targeting neuroendocrine
activation provided the strongest evidence that the development
of cachexia can be prevented by an average of 8 months. He
concluded by stating that fat represents energy that is required to
maintain function during disease states and the level of fat tissue
has been shown to be a positive predictor of survival.
Energy metabolism with HIV
Dr Derek Macallan (St George’s Hospital, London) suggested that
many patients with AIDS were dying from their starvation as well
as the disease process. However, unlike cardiac cachexia, fat mass
correlated very poorly with survival in patients with AIDS. He said
that there was a lot of heterogeneity of mechanisms of weight loss
in AIDS and this could well apply to cancer since there are many
forms of cancer. For example, patients with opportunistic
infections lost weight during the infection but regained some
following recovery, but patients with chronic diarrhoea lost weight
progressively, with no weight gain. In patients with AIDS and
pneumonia, REE increased and lean tissue was preferentially
depleted as adipose tissue was preserved, but in protozal diarrhoea
REE decreased and adipose tissue was utilised (Macallan et al,
1995). He suspected that this could also be the case with cancer
patients who would also experience a mix of starvation and
catabolic responses.
SUMMARY
It was agreed that investigation of the mechanisms of cachexia in
different disease states could provide informative data with which
to develop a multimodal therapeutic approach to this important
clinical syndrome. There was a need for more multidisciplinary
working especially bridging from academic science clinical to
oncologists.
Following the Workshop, both MRC and CR UK wished to
encourage high-quality research proposals, and, where appro-
priate, a multidisciplinary approach was to be encouraged.
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